<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955147</url>
  </required_header>
  <id_info>
    <org_study_id>2016P000932</org_study_id>
    <nct_id>NCT02955147</nct_id>
  </id_info>
  <brief_title>Ustekinumab for the Treatment of Giant Cell Arteritis</brief_title>
  <acronym>UGCA</acronym>
  <official_title>Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ustekinumab is effective in the treatment
      of Giant Cell Arteritis (GCA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of ustekinumab, an
      interleukin (IL)-12/23 inhibitor, in patients with GCA

      Hypothesis IL-12/23 pathway blockade may maintain disease remission in patients with GCA

      Specific Aims

        -  To evaluate the safety and tolerability of ustekinumab administration in 20 patients
           with GCA

        -  To evaluate the efficacy of ustekinumab for remission maintenance and glucocorticoid
           sparing in 20 patients with GCA
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inefficacy
  </why_stopped>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Actual">September 19, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients in Glucocorticoid-free Remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>The primary study endpoint, prednisone-free remission, was defined as: 1) absence of relapse from the time that remission was achieved through week 52; 2) normalization of ESR (&lt;40 mm/hour) and CRP (&lt;10 mg/L); and, 3) adherence to the protocol prednisone taper.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disease Flare</measure>
    <time_frame>52 weeks</time_frame>
    <description>Disease relapse was defined as the recurrence of signs or symptoms of GCA (e.g., cranial or PMR) that required treatment intensification, regardless of the ESR and CRP levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Prednisone Dose</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With at Least One Adverse Event</measure>
    <time_frame>52 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <condition>Temporal Arteritis</condition>
  <condition>Horton's Disease</condition>
  <arm_group>
    <arm_group_label>Ustekinumab plus prednisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling</description>
    <arm_group_label>Ustekinumab plus prednisone</arm_group_label>
    <other_name>Stelara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone is an anti-inflammatory medication</description>
    <arm_group_label>Ustekinumab plus prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must meet the following criteria

          1. Able and willing to provide written informed consent and to comply with the study
             protocol

          2. Diagnosis of GCA classified according to the following criteria:

               -  Age 50 years or older

               -  History of erythrosedimentation rate (ESR) ≥ 50 mm/hour or C-reactive protein
                  (CRP) ≥ 10 mg/L

             AND at least one of the following:

               -  Cranial symptoms of GCA

               -  Symptoms of polymyalgia rheumatica (PMR)

             AND at least one of the following:

               -  Temporal artery biopsy revealing features of GCA

               -  Evidence of large-vessel vasculitis by angiography or cross-sectional imaging

          3. Active new-onset or relapsing active disease

        Exclusion Criteria:

          1. Allergies: Subjects who have history of previous severe allergic or anaphylactic
             reaction associated with the administration of monoclonal antibodies or antibody
             fragments.

          2. Systemic infection: Subjects who have an active systemic infection.

          3. Serious infection: Subjects who have had serious infections, or any major episode of
             infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of
             enrollment.

          4. Chronic or recurrent infection: Subjects who have chronic or recurrent bacterial,
             viral, fungal, mycobacterial, or protozoan infection.

          5. Opportunistic infection: Subjects who have, or have had, an opportunistic infection
             within 6 months prior to enrollment.

          6. Subjects who have active hepatitis B or active hepatitis C or a documented history of
             HIV

          7. Latent tuberculosis infection

          8. Malignancy

          9. Subjects with evidence of serious uncontrolled concomitant cardiovascular, nervous
             system, pulmonary, renal, hepatic, endocrine, immunologic, psychiatric or
             gastrointestinal disease that could interfere with participation in the trial
             according to the protocol.

         10. Subjects with transplanted organs (with the exception of a corneal transplant &gt; 3
             months prior to screening)

         11. Major surgery within 8 weeks prior to Screening or planned major surgery within 12
             months after Baseline

         12. Pregnancy

         13. The following laboratory abnormalities

               -  Hemoglobin &lt; 8 gr/dL

               -  Platelets &lt; 100/mm3

               -  White blood cell count (WBC) &lt; 3000/mm3

               -  Absolute neutrophil count &lt; 2000/mm3

               -  Absolute lymphocyte count &lt; 500/mm3

               -  Serum creatinine &gt; 1.4 mg/dL in female subjects and &gt; 1.6 mg/dL in male subjects

               -  Total bilirubin &gt; 2 mg/dL

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 1.5 X upper
                  limit of normal

               -  Positive hepatitis B surface antigen, hepatitis B core antibody or hepatitis C
                  antibody

         14. Prohibited medications:

               -  Subjects who received methotrexate (MTX) &gt; 30 mg weekly, azathioprine,
                  mycophenolate mofetil, cyclophosphamide, chlorambucil, tacrolimus, leflunomide,
                  canakinumab, belimumab, abatacept, tocilizumab, secukinumab, infliximab,
                  etanercept, adalimumab, golimumab, or certolizumab within the 3-month period
                  prior to enrollment.

               -  Subjects who had treatment with any anti-cluster designation antigen (CD)20 agent
                  (e.g., rituximab) within the 9-month period prior to enrolment

               -  Subjects who used any investigational drug within 1 month prior to enrollment or
                  within 5 half-lives of the investigational agent, whichever is longer.

               -  Low dose MTX: Patients on &lt; 30 mg of MTX weekly will be eligible for enrollment
                  after a 2-week washout interval before receiving ustekinumab

               -  Vaccines: Subjects who received any live virus or bacterial vaccinations other
                  than bacille Calmette-Guerin (BCG) within the 3 months before the first
                  administration of the study agent, or are expected to receive any live virus or
                  live bacterial vaccinations during the study, or up to 3 month after the last
                  administration of ustekinumab are not eligible. Subjects who received BCG
                  vaccines within the 12 months before the first administration of the study agent,
                  or are expected to receive BCG vaccines during the study, or up to 12 month after
                  the last administration of ustekinumab are also not eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <results_first_submitted>April 29, 2020</results_first_submitted>
  <results_first_submitted_qc>June 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2020</results_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sebastian H Unizony, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02955147/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02955147/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between December 2016 and August 2018, we screened 16 GCA patients for this trial. Three patients failed the screening process and 13 patients were enrolled.</recruitment_details>
      <pre_assignment_details>Three patients failed the screening due to dementia (N = 1), severe prednisone-induced depression (N = 1), and positive hepatitis B core antibody (N = 1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ustekinumab Plus Prednisone</title>
          <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
Ustekinumab: Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone was chosen by the investigators according to disease severity and comorbid medical conditions. The initial prednisone dose was 60 mg in 3 patients, 40 mg in 9 patients, and 20 mg in 1 patient.
Prednisone is an anti-inflammatory medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ustekinumab Plus Prednisone</title>
          <description>Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases.
Ustekinumab: Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
Prednisone: Prednisone is an anti-inflammatory medication</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients in Glucocorticoid-free Remission</title>
        <description>The primary study endpoint, prednisone-free remission, was defined as: 1) absence of relapse from the time that remission was achieved through week 52; 2) normalization of ESR (&lt;40 mm/hour) and CRP (&lt;10 mg/L); and, 3) adherence to the protocol prednisone taper.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ustekinumab Plus Prednisone</title>
            <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg (n = 3), 40 mg (n = 9) or 20 mg (n = 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Glucocorticoid-free Remission</title>
          <description>The primary study endpoint, prednisone-free remission, was defined as: 1) absence of relapse from the time that remission was achieved through week 52; 2) normalization of ESR (&lt;40 mm/hour) and CRP (&lt;10 mg/L); and, 3) adherence to the protocol prednisone taper.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disease Flare</title>
        <description>Disease relapse was defined as the recurrence of signs or symptoms of GCA (e.g., cranial or PMR) that required treatment intensification, regardless of the ESR and CRP levels.</description>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ustekinumab Plus Prednisone</title>
            <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg (n = 3), 40 mg (n = 9) or 20 mg (n = 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Flare</title>
          <description>Disease relapse was defined as the recurrence of signs or symptoms of GCA (e.g., cranial or PMR) that required treatment intensification, regardless of the ESR and CRP levels.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Prednisone Dose</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ustekinumab Plus Prednisone</title>
            <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg (n = 3), 40 mg (n = 9) or 20 mg (n = 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Prednisone Dose</title>
          <units>mg of prednisone</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2289" spread="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With at Least One Adverse Event</title>
        <time_frame>52 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ustekinumab Plus Prednisone</title>
            <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg (n = 3), 40 mg (n = 9) or 20 mg (n = 1).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ustekinumab Plus Prednisone</title>
          <description>Ustekinumab 90 mg was administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.
Ustekinumab: Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
All patients received a 6 month prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone was chosen by the investigators according to disease severity and comorbid medical conditions. The initial prednisone dose was 60 mg in 3 patients, 40 mg in 9 patients, and 20 mg in 1 patient.
Prednisone is an anti-inflammatory medication</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <description>One patient developed mild diverticulitis, which was classified as a serious adverse event because it required hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sebastian Unizony</name_or_title>
      <organization>Mass General Hospital</organization>
      <phone>(617) 726-7938</phone>
      <email>sunizony@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

